Ceftibuten

Ceftibuten
Clinical data
Trade names	Cedax
AHFS/Drugs.com	Monograph
MedlinePlus	a698023
ATC code	J01DD14 (WHO) ;
Identifiers
	IUPAC name (6R,7R)-7-([(Z)-2-(2-Amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	97519-39-6 ;
PubChem CID	5282242;
DrugBank	DB01415 ;
ChemSpider	4445419 ;
UNII	IW71N46B4Y;
KEGG	D00922 ;
ChEBI	CHEBI:3510 ;
ChEMBL	ChEMBL1605 ;
CompTox Dashboard (EPA)	DTXSID4045925 ;
ECHA InfoCard	100.238.211
Chemical and physical data
Formula	C15H14N4O6S2
Molar mass	410.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC(=O)O)\c3nc(sc3)N)C(=O)O;
	InChI InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1 ; Key:UNJFKXSSGBWRBZ-BJCIPQKHSA-N ;
	(verify)

Ceftibuten is a third-generation cephalosporin antibiotic.^[1]^[2] It is an orally administered agent, with two dosage forms, capsule or oral suspension. It is marketed by Pernix Therapeutics under the trade name Cedax.

^ Owens RC, Nightingale CH, Nicolau DP (1997). "Ceftibuten: an overview". Pharmacotherapy. 17 (4): 707–20. doi:10.1002/j.1875-9114.1997.tb03746.x. PMID 9250548. S2CID 32735943.
^ Guay DR (September 1997). "Ceftibuten: a new expanded-spectrum oral cephalosporin". The Annals of Pharmacotherapy. 31 (9): 1022–33. doi:10.1177/106002809703100913. PMID 9296244. S2CID 39852306.

[Owens_1997-1] Owens RC, Nightingale CH, Nicolau DP (1997). "Ceftibuten: an overview". Pharmacotherapy. 17 (4): 707–20. doi:10.1002/j.1875-9114.1997.tb03746.x. PMID 9250548. S2CID 32735943.

[Guay_1997-2] Guay DR (September 1997). "Ceftibuten: a new expanded-spectrum oral cephalosporin". The Annals of Pharmacotherapy. 31 (9): 1022–33. doi:10.1177/106002809703100913. PMID 9296244. S2CID 39852306.

[1]

[2]